Redwood Investment Management LLC Invests $1.34 Million in Medpace Holdings, Inc. $MEDP

Key Points

• Redwood Investment Management LLC has acquired a new stake in Medpace Holdings, purchasing 4,402 shares valued at approximately $1.34 million during the first quarter.
• Medpace reported $3.10 earnings per share (EPS) for the last quarter, exceeding estimates and demonstrating a 14.2% year-over-year revenue increase to $603.31 million.
• Insiders sold a total of 114,450 shares of Medpace stock worth over $51 million in the last quarter, indicating a significant offloading of shares by corporate insiders.

Redwood Investment Management LLC purchased a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,402 shares of the company's stock, valued at approximately $1,341,000.

A number of other large investors have also added to or reduced their stakes in MEDP. Brooklyn Investment Group raised its stake in Medpace by 244.8% in the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after acquiring an additional 71 shares during the period. Whittier Trust Co. raised its stake in Medpace by 47.3% in the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after acquiring an additional 35 shares during the period. Colonial Trust Co SC raised its stake in Medpace by 150.0% in the 4th quarter. Colonial Trust Co SC now owns 175 shares of the company's stock valued at $58,000 after acquiring an additional 105 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new stake in Medpace in the 1st quarter valued at $60,000. Finally, Assetmark Inc. raised its stake in Medpace by 24.9% in the 1st quarter. Assetmark Inc. now owns 216 shares of the company's stock valued at $66,000 after acquiring an additional 43 shares during the period. Institutional investors own 77.98% of the company's stock.

Medpace Stock Performance

MEDP opened at $469.29 on Wednesday. The firm has a market cap of $13.18 billion, a P/E ratio of 34.89, a price-to-earnings-growth ratio of 2.94 and a beta of 1.42. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $501.30. The business's fifty day moving average is $385.60 and its 200-day moving average is $336.58.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.00 by $0.10. The company had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.Medpace's quarterly revenue was up 14.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Activity at Medpace

In other news, CFO Kevin M. Brady sold 12,000 shares of the stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the sale, the chief financial officer directly owned 6,000 shares of the company's stock, valued at approximately $2,725,380. This represents a 66.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Cornelius P. Mccarthy III sold 1,662 shares of the company's stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $465.04, for a total value of $772,896.48. Following the sale, the director owned 10,197 shares of the company's stock, valued at approximately $4,742,012.88. This represents a 14.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 114,450 shares of company stock worth $51,791,251 in the last quarter. 20.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on MEDP. Barclays increased their price target on Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. Mizuho increased their price target on Medpace from $328.00 to $510.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. William Blair restated a "market perform" rating on shares of Medpace in a research note on Wednesday, July 23rd. Cowen lowered Medpace from a "buy" rating to a "sell" rating in a report on Wednesday, July 23rd. Finally, Robert W. Baird upped their price objective on Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, Medpace presently has an average rating of "Reduce" and a consensus target price of $406.60.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.